Literature DB >> 15342008

Neuroimmunology of the paraneoplastic neurological degenerations.

Wendy K Roberts1, Robert B Darnell.   

Abstract

The paraneoplastic neurological degenerations (PNDs) are remarkable examples of naturally occurring tumor immunity in humans. In PND patients, common tumors such as breast, ovarian and lung tumors express proteins normally made exclusively in the brain, eliciting an immune response that successfully suppresses growth of the tumor. This successful anti-tumor response would be expected to go clinically unnoticed by the patient, but the immune cells mediating the response somehow cross into the brain, resulting in an autoimmune attack on neurons and neurological symptoms. Pieces of the mystery of this tumor immune response and neuronal autoimmunity have been assembled, but much more needs to be learned.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342008     DOI: 10.1016/j.coi.2004.07.009

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  16 in total

1.  Encephalitis with herpes simplex-2 in the cerebrospinal fluid and anti-RI (ANNA-2) antibodies: an infectious or a paraneoplastic syndrome?

Authors:  Jan Novy; Antonio Carota; Philippe Eggimann; Marc Pusztaszeri; Andrea O Rossetti; Renaud Du Pasquier
Journal:  BMJ Case Rep       Date:  2009-08-11

2.  Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.

Authors:  Adriaan H C de Jongste; Marieke T de Graaf; Emanuela Martinuzzi; Patricia D M van den Broek; Jaco Kraan; Cor H J Lamers; Roberto Mallone; Jan W Gratama; Peter A E Sillevis Smitt
Journal:  Neuro Oncol       Date:  2012-05-15       Impact factor: 12.300

3.  RNA regulation in neurologic disease and cancer.

Authors:  Robert B Darnell
Journal:  Cancer Res Treat       Date:  2010-09-30       Impact factor: 4.679

4.  The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells.

Authors:  Kevin J O'Donovan; Jennifer Diedler; Graeme C Couture; John J Fak; Robert B Darnell
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

5.  A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

Authors:  Adriaan H de Jongste; Teun van Gelder; Jacoline E Bromberg; Marieke T de Graaf; Jan W Gratama; Marco W Schreurs; Herbert Hooijkaas; Peter A Sillevis Smitt
Journal:  Neuro Oncol       Date:  2014-07-03       Impact factor: 12.300

6.  Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.

Authors:  S E Monstad; A Storstein; A Dørum; A Knudsen; P E Lønning; H B Salvesen; J H Aarseth; C A Vedeler
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

7.  Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.

Authors:  Wendy K Roberts; Ilana J Deluca; Ashby Thomas; John Fak; Travis Williams; Noreen Buckley; Athanasios G Dousmanis; Jerome B Posner; Robert B Darnell
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

8.  Modulator of Apoptosis 1: A Highly Regulated RASSF1A-Interacting BH3-Like Protein.

Authors:  Jennifer Law; Victor C Yu; Shairaz Baksh
Journal:  Mol Biol Int       Date:  2012-06-14

Review 9.  Paraneoplastic neurological syndromes.

Authors:  Jérôme Honnorat; Jean-Christophe Antoine
Journal:  Orphanet J Rare Dis       Date:  2007-05-04       Impact factor: 4.123

10.  A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease.

Authors:  Wendy K Roberts; Nathalie E Blachère; Mayu O Frank; Athanasios Dousmanis; Richard M Ransohoff; Robert B Darnell
Journal:  Ann Neurol       Date:  2015-08-21       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.